Welcome to CM Online Store!
Antibody Drug Conjugate Kits!
AqT bioconjugates coming soon!
Shop by Brand
ADC Kits
CellMosaic ADC PerKits®
| Download Documents | |
| APPLICATION NOTE |
Historically, antibody-drug conjugation was performed solely by drug developers, occasionally in collaboration with contract research organization (CRO). The cost of these services can be prohibitive for academia institutions and small biotech companies. During the screening stages, researchers often need to prepare various ADCs with different antibodies and drugs.
CellMosaic's ADC PerKits® are designed to prepare antibody-drug conjugates through surface amines or reduced thiols. Some kits are applicable for general payloads with specific functional groups, while others provide selected standard linker molecules conjugated to a chosen payload. Each kit includes the necessary reagents and protocols for attaching the selected payload to the customer’s antibody and purifying the final ADC. Customers only need to supply their antibody and standard lab equipment.
A typical CellMosaic personalized ADC kit yields approximately 2-3 mg of final ADC in buffer, with an average Drug-to-Antibody Ratio (DAR) of 2-4. Purity levels are typically >90%, with less than 5% unreacted payload remaining. Individual results may vary depending on the specific antibody system you are using and the hydrophobicity of your payload. The kit instructions are comprehensive and easy to follow, and the procedure can typically be completed within 4 to 6 hours, requiring less than 1 hour of hands-on time.
CellMosaic launched the first ADC PerKit® on its website in 2017, the first kit of its kind on the market. Since then, we have continuously enhanced the platform to make it more robust and easy to use. As of February 2026, 187+ organizations worldwide have used CellMosaic’s ADC kits and related reagents.
See the publications using CellMosaic's ADC PerKits® below.
Other products on the market for antibody screening may use a general secondary antibody or a general antibody affinity coupling (such as protein-A) to provide indirect conjugation. However, these indirect conjugation approaches can significantly affect the hydrodynamic size and physiological behaviors of ADCs (e.g., altering cleavage and degradation mechanisms). As a result, these products do not provide a fully representative approach for evaluating your novel ADC in screening or proof-of-concept (POC) studies.
PerKit® ADC Selection Guide
Product# |
Drug |
Mechanism of Action |
Protein |
Labeling Chemistry |
Linkage |
Scale of Reaction (Standard Kit) |
| CM11431 | Deruxtecan | Topoisomerase I Inhibitor | IgG Ab | Reduced thiol | Releasable (GGFG) | 1-3 mg |
| CM11434 | Deruxtecan (HL) | Topoisomerase I Inhibitor | IgG Ab | Reduced thiol | Releasable (GGFG) | 1-3 mg |
| CM11435 | Exatecan | Topoisomerase I Inhibitor | Ab or Protein | Surface amine | Stable | 6.67-20 nmol |
| CM11436 | Exatecan | Topoisomerase I Inhibitor | Ab or Protein | Surface amine | Releasable (VC-PAB) | 6.67-20 nmol |
| CM11408 | SN38 | Topoisomerase I Inhibitor | IgG Ab | Surface amine | Releasable (ester) | 1-3 mg |
| CM11438 | SN38 | Topoisomerase I Inhibitor | Ab or Protein | Surface amine | Releasable (VC-PAB) | 6.67-20 nmol |
| CM11410 | DM1 | Tubulin Polymerization Inhibitor | IgG Ab | Surface amine | Stable | 0.1 mg, 1-3 mg |
| CM11419 | DM1 | Tubulin Polymerization Inhibitor | F(ab')2 | Surface amine | Stable | 0.73-2.2 mg |
| CM11409 | MMAE | Tubulin Polymerization Inhibitor | IgG Ab | Reduced thiol | Releasable (VC-PAB) | 0.1 mg, 1-3 mg |
| CM11416 | MMAE | Tubulin Polymerization Inhibitor | F(ab')2 | Reduced thiol | Releasable (VC-PAB) | 0.73-2.2 mg |
| CM11422 | MMAF | Tubulin Polymerization Inhibitor | IgG Ab | Reduced thiol | Stable | 1-3 mg |
| CM11425 | MMAF | Tubulin Polymerization Inhibitor | IgG Ab | Reduced thiol | Releasable (VC-PAB) | 1-3 mg |
| CM11407 | Methotrexate | Dihydrofolate Reductase (DHFR) Inhibitor | IgG Ab | Surface amine | Stable | 1-3 mg |
| CM11406 | Doxorubicin | DNA Intercalation, Topoisomerase II inhibitor | IgG Ab | Surface amine | Stable | 1-3 mg |
| CM11433 | UM171 | Proteasomal Degradation | IgG Ab | Surface amine | Stable | 1-3 mg |
| CM11439 | PBD Dimer | DNA Binding | Ab or Protein | Surface amine | Releasable (VA) | 0.1 mg IgG, 6.67-20 nmol |
| CM11429 | No drug (VC-PAB linker only) | No drug (VC-PAB linker only) | IgG Ab | Reduced thiol | Releasable (VC-PAB) | 1-3 mg |
| CM51403 | Acid | N/A (Customer Supplied) | IgG Ab | Surface amine | Stable | 1-3 mg |
AqT® ADC Drug Development & ManufacturingWhen conventional linkers fail to enable drug conjugation or when the therapeutic efficacy of an ADC is hindered by payload limitations, CellMosaic has developed a breakthrough solution: AqueaTether® (AqT®) linkers. These super-hydrophilic, high-loading linkers are designed to enhance payload solubility, stability, and conjugation efficiency, overcoming key challenges in ADC development. To explore the full potential of AqT® technologies, click here. Interested in integrating this cutting-edge platform into your novel ADC development? Learn more here. |
Selected Citations from Customers who Used CellMosaic's Kits to Prepare their ADC
Lofgren, K. A.; Sreekumar, S.; Jenkins, C. E., Jr.; Ernzen, K. J.; Kenny, P. A. Anti-tumor efficacy of an MMAE-conjugated antibody targeting cell surface TACE/ADAM17-cleaved Amphiregulin in breast cancer. Antibody Therapeutics 2021, 4(4), 252-261. DOI: 10.1093/abt/tbab026
Kierkels, G. J. J.; van Diest, E.; Hernández-López, P.; Scheper, W; de Bruin, A.C.M.; Frijlink, E; Aarts-Riemens, T; van Dooremalen, S. F. J.; Beringer, D. X.; Oostvogels, R; Kramer, L.; Straetemans, T.; Uckert, W.; Sebestyén, Z.; Kuball, J. Characterization and modulation of anti-αβTCR antibodies and their respective binding sites at the βTCR chain to enrich engineered T cells Molecular Therapy-Methods & Clinical Development 2021, 22, 388-400. DOI:10.1016/j.omtm.2021.06.011
Parameswaran, N.; Luo L.; Zhang, L.; Chen, J.; DiFilippo, F. P.; Androjna, C.; Fox, D. A.; Ondrejka, S. L.; Hsi, E. D.; Jagadeesh, D.; Lindner, D. J.; Lin, F. CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma Leukemia 2023, 37, 2050-2057. DOI:10.1038/s41375-023-01997-8
Zhang, L; Luo, L.; Chen, J. Y.; Singh, R.; Baldwin III, W. M.; Fox, D. A.; Lindner, D. J.; Martin, D. F.; Caspi, R. R.; Lin, F. A CD6-targeted antibody-drug conjugate as a potential therapy for T cell–mediated disorders JCI Insight 2023, 8(23), e172914. DOI:10.1172/jci.insight.172914
Sun, Z.; Chu, X.; Adams C.; Ilina, T. V.; Guerrero, M.; Lin, G.; Chen, C.; Jelev, D.; Ishima, R.; Li, W.; Mellors, J. W.; Calero, G.; Dimitrov, D. S. Preclinical assessment of a novel human antibody VH domain targeting mesothelin as an antibody-drug conjugate Molecular Therapy-Oncolytics 2023, 31,100726. DOI: 10.1016/j.omto.2023.09.002
Hou, J; Uejima, T.; Tanaka, M.; Lee Son, Y.; Hanada, K.; Kukimoto-Niino, M.; Yamaguchi, S.; Hashimoto, S.; Yokoyama, S.; Takemori, T.; Saito, T.; Shirouzu, M.; Kondo, T. EVA1-antibody drug conjugate is a new therapeutic strategy for eliminating glioblastoma-initiating cells Neuro-Oncology 2024, 27(3), 682-694. DOI: 10.1093/neuonc/noae226
Micalizzi, D. S.; Che, D.; Nicholson, B. T.; Edd, J. F.; Desai, N.; Lang, E. R.; Toner, M.; Maheswaran, S.; Ting, D. T.; Haber, D. A. Targeting breast and pancreatic cancer metastasis using a dual-cadherin antibody. PNAS 2022, 119(43), e2209563119. DOI: 10.1073/pnas.2209563119
Semenova, G.; Frank, S.; Dumpit, R.; Han, W.; Coleman, I.; Gulati, R.; Morrissey, C.; Haffner, M. C.; Nelson, P. S.; Lee, J. K. Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer, Ver. 1. bioRxiv September 11, 2025. DOI: 10.1101/2025.09.05.674562